Tilray Brands said it acquired the Lyphe Group, a U.K.-based medical cannabis clinic and digital pharmacy platform that has dispensed about 150,000 units and treated more than 16,000 patients to date, expanding Tilray Medical’s footprint in Europe.
The company said the Lyphe deal creates its first fully vertically integrated medical platform, combining cannabis cultivation and production with clinical care, dispensing, and pharmaceutical distribution. Tilray said it expects the business to be accretive in 2027.
On the beverage side, Tilray said that six weeks after buying BrewDog it has stabilized brewing volumes, maintained service levels, and begun onboarding new distribution and strategic partners. It said BrewDog is expected to be cash flow positive in 2027. Tilray also said it plans to invest in a “brewpub of the future” at one existing location and is targeting expansion in the U.K., Australia, and the U.S., with additional focus on the Middle East and India.
Tilray said demand for its American craft portfolio is rising in the U.K. and that it plans to launch Hi*Ball Energy there in May.
In the U.S., Tilray said it is tracking medical cannabis rescheduling and is evaluating participation in a Medicare and Medicaid Innovation pilot program that would supply hemp-derived medical cannabis to underserved patients.
To fund expansion, Tilray filed an at-the-market equity program for up to $180 million. The market has reacted to these announcements by moving the company's shares -5.76% to a price of $6.54. For the full picture, make sure to review Tilray Brands's 8-K report.
